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Introduction.  This article aims to present the rules concerning the protection and ownership of the results of scientific 
research and development works and related know-how, including those jointly generated in multicentre research projects.
Material and methods.  The analysis focuses on the identification of types of medical research results and the possibility 
of protecting them under intellectual property law, including copyright, patent and unfair competition law. It also con-
siders regulations providing provisions on the ownership and commercialisation of R&D results acquired under research 
programmes, projects and sponsored research, including clinical trials.   
Results.  The lack of protection of research results as such by intellectual property rights, the different nature of those results, 
as well as potential conflicts of interests that arise from the exploitation of data which has both scientific and market value, 
may in practice cause problems in regard to who is entitled to them and what are the rules for their use and publication. 
Situations of conflict may arise at the interface between the interests of the different actors involved in conducting and 
financing research (researchers, research centres, sponsors).
Conclusion.  Effective management of research and development results requires identification of the appropriate regime 
(statutory, project or contractual) under which they were obtained and are going to be exploited. Although the rules in 
force for the acquisition of rights can only be modified contractually to a certain extent, it is strongly recommended to 
supplement them with detailed contractual provisions specifying the rules for the co-ownership of results, the rights and 
obligations of the entities involved in the research, as well as ensuring confidentiality and restrictions on their disclosure 
with and/or without the consent of co-authors and sponsors financing research.
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of research results.
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Introduction
Research results lack uniform rules on their protection, owner-
ship, and exploitation. There are additional aspects to this pro-
blem with regard to medical research results, which include the 
need to transfer them into practice, financing costly research, 
meeting administrative requirements for the authorization of 
medical products, ensuring ethical standards and protecting 
the privacy of individuals in clinical trials. Thus, medical research 
results have an important characteristic: they are not purely 
scientific, but most often utilitarian and commercial, and in 
terms of their ownership and accessibility, the interests of 
individual scientists, research sponsors and members of so-
ciety should be considered, who claim the right of freedom 
of research and the right to access to the latest treatments for 
the protection of their health.
Material and methods
The starting point for establishing rules for the protection and 
acquisition of rights to research results is to clarify this term, 
which in the field of medicine may relate to scientific discove-
ries, concepts and hypotheses (in particular those related to 
the use of new substances and therapies), the results of clinical 
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research and assessments, tests, medical experiments, biome-
dical, epidemiological, behavioral research, results obtained 
through screening programmes, diagnostic tests, treatment 
trials, as well as the results of medical technology research and 
factors influencing health. A separate category is made up of 
results used in specific products and technologies applied 
in medicine. Such a heterogeneous group determines the 
problems in regard to the legal grounds for determining the 
ownership of results [1]. This applies especially to the results of 
studies conducted jointly by many research centres (domestic 
and foreign), and results obtained in sponsored clinical trials 
that are subject to specific statutory regulations.
Although the intuitive regime protecting the results of 
research and development activity is intellectual property 
law – contrary to common belief – this does not provide tools 
for the protection of research results as such, even though 
they have undeniable scientific, commercial and application 
value. The results of research and scientific activities, including 
the results of clinical trials as numerical data, parameters and 
statistics, are not subject to copyright or patent protection, 
and thus the regulations do not provide for the acquisition 
of exclusive intellectual property rights to them [2]. A legal 
monopoly on the results of medical research is not available 
in order to not limit the access of society to such results and to 
allow the execution of a constitutionally guaranteed principle 
of freedom of research. Even though entities conducting rese-
arch do not acquire property rights to the results, they retain 
a kind of “authorship” of the results under the protection of 
personal rights which ensures affiliation with research results.
The absence of exclusive rights to the results of research 
does not preclude their actual or contractual monopolization 
as data possessing certain scientific or market value. Exclusi-
ve intellectual property rights may be acquired to works in 
which research results have been described, discussed and 
verified (scientific articles, conference posters presenting re-
sults, reports, studies, databases containing results). Inventions 
which use these results can be also patented. According to the 
general ownership regimes of IP rights, an author’s economic 
rights to a work or the right to obtain a patent for an invention 
are vested in the author or co-authors on the principle of the 
commonality of rights (Article 8 and 9 of the Copyright Act and 
Article 11 paragraph 1 and 2 of the Industrial Property Act). 
If such creations have been created by an employee in the 
performance of his/her duties, the rights are acquired by the 
employer which employs the scientist (researcher), unless the 
employment contract provides for other rules in this respect 
(Article 12 of the Copyright Act and Article 11 paragraph 3 of 
the Industrial Property Act). Depending on the contractual 
arrangements for the involvement of an individual participant 
in the research, in the case of multicentre research, rights may 
be acquired by the centres employing them or those individu-
als (if they are researching on a basis other than a contract of 
employment or outside of their employment obligations). The 
exception to this rule concerns employee copyrighted scienti-
fic works created in universities and research centres, to which 
the author’s economic rights are vested in the employees and 
not in the research unit. The latter has only a legally guaranteed 
right to the first publication of the scientific work (Article 14 of 
the Copyright Act). Due to the competition of scientific centres 
regarding the affiliation of publications containing the most 
current or pioneering research results, collisions in the exercise 
of priority rights concerning co-publications involving authors 
from different centres are possible.
Results
Despite the exclusion of research results from intellectual pro-
perty law protection, it is possible to acquire actual exclusivity 
of results which have market applicability and value by safegu-
arding their confidentiality. The legal basis for the protection 
of confidential research results is the Act on Combating Unfair 
Competition of 16 April 1993 [3]. According to Article 11 of 
this regulation that has recently been harmonized with EU 
standards, it is possible to protect such results as a so-called 
company secret (confidential know-how) from disclosure, use 
or unauthorized acquisition, provided that they are not gene-
rally known to persons normally dealing with such results or are 
not easily accessible to such persons and the entity entitled to 
the results has taken steps, with due diligence, to keep them 
confidential. The requirement to take steps to keep results 
confidential should be implemented in practice, in particular 
by signing clauses or confidentiality agreements with em-
ployees, members of research teams, researchers involved in 
sponsored trials, clinical trial or health technology assessments. 
The right to use or dispose of results whose market value is 
due to their confidentiality may belong to the research team 
or centres where the research is conducted or the research 
sponsor. Disclosure or obtaining such results shall constitute 
an act of unfair competition, if it occurs without the consent of 
the rightsholder and results from unauthorized access, misap-
propriation, or the copying of documents, objects, materials, 
substances or  electronic files containing the results. Obtaining 
results identical to somebody else’s confidential know-how is 
permissible when it has occurred as a result of independent 
discovery, production, observation, research, or testing, or 
to protect a legitimate public interest (e.g. to avoid the use 
of falsified or unreliable results of medical research, for the 
functioning of the health care system, obtaining permission 
to market a medicine, etc.).  
In addition to the general statutory regulations, the provi-
sions providing for who is entitled to research results, what the 
rules are for their use, publication and commercialisation may 
result from separate statutory or contractual regulations, inclu-
ding agreements with clinical trial sponsors or research funding 
schemes for national and international research projects.
In the coming years, the most important research funding 
mechanism for Polish researchers in the EU will be Horizon 
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Europe 2021–2027, which also provides, under priority research 
areas, funding for research in the area of health. Although the 
EU regulation on participation in research projects imple-
mented under the program is not yet approved, it will set out 
detailed rules, binding for participants, on the management 
of research results obtained from projects financed from this 
source in regard to the ownership of research results, obliga-
tions related to their protection and dissemination and the 
granting of so-called access rights to them [4]. 
At the national level, specific provisions on the manage-
ment of and know-how related to research and development 
results are laid down in the Act on Higher Education and 
Science of 20 July 2018 and the Act on Research Institutes of 30 
April 2010 [5]. Issues concerning the ownership of the results of 
research projects financed from the resources of the National 
Centre for Science (NCN) and the National Centre for Research 
and Development (NCBiR) are regulated by the respective acts 
[6] and may be subject to specific rules for the implementation 
of strategic programs (such as, for example, NCBiR’s program 
“Prevention and treatment of civilization diseases” – STRATEG-
ME). As far as intellectual property rights are concerned, they 
respect the general principles of acquiring rights indicated 
earlier, by mentioning that, in the case of results obtained in 
NCN and NCBiR projects, they belong to the entity to which 
the funds have been allocated unless an agreement between 
the Centre and the entity receiving the funds or the decision 
to allocate funds provides otherwise [6]. 
Independent standards apply to the results of clinical trials, 
both commercial and non-commercial, which, at the national 
level, are provided for in the Pharmaceutical Law of 6 Septem-
ber 2001 [7] and the implementing Act on Good Clinical Prac-
tice [8]. It follows from these regulations that the ownership of 
clinical trial results is vested in the sponsor, who may transfer 
the ownership of all or part of the data or the right to dispose 
of all or part of the data related to the clinical trial to another 
entity by means of a written agreement. The limitations in use 
and transfer apply to results generated in non-commercial 
clinical trials, i.e. where the owner of the results generated in 
the course of the clinical trial is a university or other scientific 
institution, investigator or organization of researchers. The 
results of non-commercial clinical trials are intended to serve 
cognitive, scientific, non-commercial purposes and may be 
disseminated, for example, through scientific publications. 
However, they may not be used for marketing purposes or to 
make changes to an existing marketing authorization required 
for a medicinal product to be put on the market.
Conclusion
On the one hand, research results as such do not constitute 
an independent object of protection, on the other hand, they 
are an essential element required for the development and 
marketing of medical products and services. This may cause 
a conflict of interest between the free use of research results 
and making them available to the public (in particular by 
publishing them as soon as possible in scientific journals or as 
part of conference speeches) and maintaining their confiden-
tiality (novelty), necessary for market monopolization based on 
know-how or patent protection. Potential areas of conflict are 
situations where research results are obtained through joint 
research activities, where the problem of priority of their publi-
cation, joint commercialisation or use in further, independent 
research may arise. This requires the taking adoption of legal 
measures and contractual tools [9]. 
To avoid disputes concerning the ownership of results and 
their use in scientific and commercial activities, it is recom-
mended to conclude agreements on joint research work or to 
adapt model agreements relevant for a given research activity 
(such as, e.g. NCN projects, multicentre research, projects fo-
unded from EU programs). These should specify: the rules for 
the allocation of intellectual property rights generated by the 
research project or access rights to the results generated by 
joint research, as well as the rights and obligations of research 
stakeholders in the use of the results, including their publica-
tion and commercialization. The contracts should require, in 
particular, that participants keep research logs documenting 
the contributions of individuals in their research team. 
Provisions concerning the confidentiality of research 
results, the prohibition of their disclosure, the rules of noti-
fication of planned publication of results and the transfer of 
intellectual property rights should be specified in particular in 
contracts for sponsored studies, including contracts for con-
ducting clinical trials [10]. It should be borne in mind that the 
disclosure of the results of studies which have scientific value 
and validity, e.g. in an individual scientific publication or a 
research centre, may deprive such results of their application 
and market value, including preventing the funding entity 
or sponsor from obtaining exclusivity under the intellectual 
property rights system for products and technologies which 
use such results.
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